loading
Schlusskurs vom Vortag:
$2.45
Offen:
$2.45
24-Stunden-Volumen:
430.34K
Relative Volume:
0.30
Marktkapitalisierung:
$238.89M
Einnahmen:
$58.36M
Nettoeinkommen (Verlust:
$-25.72M
KGV:
-6.6012
EPS:
-0.3641
Netto-Cashflow:
$-24.91M
1W Leistung:
+4.98%
1M Leistung:
-4.22%
6M Leistung:
-49.23%
1J Leistung:
-24.64%
1-Tages-Spanne:
Value
$2.39
$2.48
1-Wochen-Bereich:
Value
$2.145
$2.555
52-Wochen-Spanne:
Value
$2.12
$5.80

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name
Firmenname
Aquestive Therapeutics Inc
Name
Telefon
908-941-1900
Name
Adresse
30 TECHNOLOGY DRIVE, WARREN, NJ
Name
Mitarbeiter
142
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
AQST's Discussions on Twitter

Vergleichen Sie AQST mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AQST
Aquestive Therapeutics Inc
2.405 283.08M 58.36M -25.72M -24.91M -0.3641
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.96 48.25B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
163.79 72.09B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.88 3.54M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.20 44.32B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.88 20.60B 16.54B -1.64B 749.00M -1.45

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-17 Eingeleitet Cantor Fitzgerald Overweight
2024-05-10 Eingeleitet Leerink Partners Outperform
2024-04-11 Eingeleitet Piper Sandler Overweight
2024-03-28 Eingeleitet Raymond James Outperform
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2019-04-22 Eingeleitet H.C. Wainwright Buy
2019-01-03 Eingeleitet Lake Street Buy
2018-08-20 Eingeleitet JMP Securities Mkt Outperform
2018-08-20 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

pulisher
01:33 AM

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World

01:33 AM
pulisher
May 19, 2025

Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 18, 2025

AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World

May 18, 2025
pulisher
May 17, 2025

Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World

May 17, 2025
pulisher
May 17, 2025

HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World

May 17, 2025
pulisher
May 17, 2025

Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN

May 17, 2025
pulisher
May 16, 2025

Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st

May 16, 2025
pulisher
May 15, 2025

Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks

May 15, 2025
pulisher
May 15, 2025

AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm - TipRanks

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 13, 2025

AQST Price Target Reduced by Piper Sandler | AQST Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Aquestive (AQST) Reports Lower Q1 Revenue, Focuses on Anaphylm L - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Aquestive Therapeutics (AQST) Anticipates FDA Milestone for Anap - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% - Investing.com

May 13, 2025
pulisher
May 13, 2025

Aquestive Therapeutics Inc Reports Q1 2025 EPS of -$0.24, Missin - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Aquestive Therapeutics: Q1 Earnings Snapshot - The Washington Post

May 12, 2025
pulisher
May 12, 2025

Earnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 Result - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials By Investing.com - Investing.com Canada

May 12, 2025
pulisher
May 12, 2025

Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c) - TipRanks

May 12, 2025
pulisher
May 12, 2025

Aquestive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Aquestive Therapeutics Submits NDA for Anaphylm - TipRanks

May 12, 2025
pulisher
May 12, 2025

Aquestive Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025
pulisher
May 10, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World

May 10, 2025
pulisher
May 10, 2025

Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Aquestive Therapeutics (AQST) Q1 Earnings Preview: Expectations and Revisions - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Raymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

May 09, 2025
pulisher
May 09, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Wells Fargo & Company MN - Defense World

May 09, 2025
pulisher
May 08, 2025

Aquestive Therapeutics at Citizens JMP: Strategic Moves in Allergy Treatment - Investing.com Australia

May 08, 2025
pulisher
May 06, 2025

Quarterly Metrics: Quick and Current Ratios for Aquestive Therapeutics Inc (AQST) - DWinneX

May 06, 2025
pulisher
May 05, 2025

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference - The Manila Times

May 05, 2025
pulisher
May 05, 2025

Aquestive Therapeutics CEO Fireside Chat: Key Updates Coming at Citizens Life Sciences Conference - Stock Titan

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Boosts Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

May 05, 2025
pulisher
May 04, 2025

Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential - Seeking Alpha

May 04, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

May 03, 2025
pulisher
May 01, 2025

Aquestive Therapeutics Inc (AQST) deserves deeper analysis - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET - The Manila Times

May 01, 2025
pulisher
Apr 30, 2025

Aquestive Therapeutics Inc (AQST) receives an Overweight rating from Cantor Fitzgerald - knoxdaily.com

Apr 30, 2025
pulisher
Apr 29, 2025

Aquestive Therapeutics Inc’s Market Journey: Closing Weak at 2.83, Down -1.39 - DWinneX

Apr 29, 2025
pulisher
Apr 28, 2025

Anaphylaxis Treatment Market Size in 7MM is expected to grow at - openPR.com

Apr 28, 2025

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$8.855
price up icon 1.03%
drug_manufacturers_specialty_generic HCM
$13.34
price down icon 0.82%
drug_manufacturers_specialty_generic RDY
$14.46
price up icon 0.03%
$122.07
price down icon 0.65%
$309.50
price up icon 1.44%
$16.82
price down icon 1.20%
Kapitalisierung:     |  Volumen (24h):